Targeted treatments for symptom domains in child and adolescent autism (Q35212468)

7 August 2017

1 reference

title

Targeted treatments for symptom domains in child and adolescent autism (English)

1 reference

7 August 2017

0 references

1 reference

1 reference

Eric Hollander

1 reference

7 August 2017

Ann T Phillips

1 reference

7 August 2017

Chin-Chin Yeh

series ordinal

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

362

1 reference

7 August 2017

issue

9385

1 reference

7 August 2017

page(s)

732-734

1 reference

Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Developing rational protocols for paediatric psychopharmacological prescribing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Risperidone in children with autism and serious behavioral problems

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Open trial of risperidone in 24 young children with pervasive developmental disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Open-label study of olanzapine in children with pervasive developmental disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

An open trial of divalproex sodium in autism spectrum disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Levetiracetam in autistic children: an open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Children with autistic spectrum disorder and a family history of affective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Use of citalopram in pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Effects of a Model Treatment Approach on Adults with Autism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

Developing strategies for psychopharmacological studies in preschool children.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914236-5

7 January 2021

10.1016/S0140-6736(03)14236-5

Identifiers

DOI

1 reference

7 August 2017

1 reference